IKS Health Q1 FY27: consolidated PAT +28% YoY to ₹193.7 Cr, margins expand

Inventurus Knowledge Solutions (IKS Health) reported consolidated revenue of ₹893.6 Cr for Q1 FY27, up 20.75% YoY (740.1 Cr) and 4.19% QoQ (857.7 Cr), with consolidated PAT of ₹193.7 Cr, up 27.84% YoY (151.5 Cr) but down 5.94% QoQ (206.0 Cr). Basic EPS rose to ₹11.56 from ₹9.07 a year ago. Consolidated NPM expanded to 21.55% from 20.39% YoY, and OPM to 33.01% from 32.12% YoY — both compressed sequentially from 23.88%/35.01% in Q4 FY26, so the YoY story is growth-with-margin-expansion while the QoQ read is a seasonal-style cooling rather than a red flag. Standalone (India-entity) PAT of ₹162.5 Cr grew a much sharper 44.0% YoY on revenue up 48.8% YoY (₹475.3 Cr) — standalone growth materially outpaced consolidated growth, reflecting that the larger, slower-growing US step-down subsidiary base (Aquity, IKS Inc.) dilutes the group number; readers comparing the two should not read the standalone print as the headline. On drivers: finance cost fell to ₹10.1 Cr from ₹18.1 Cr YoY (-44%), aiding PBT even before TruBridge's deal-financing layers on next quarter, consistent with management's stated deleveraging intent. Employee benefit expense rose to ₹455.0 Cr from ₹396.0 Cr YoY (455.0 Cr vs 418.4 Cr QoQ) and other expenses to ₹143.8 Cr from ₹106.4 Cr YoY, the main drags on the OPM print. The effective tax rate was 22.79% (tax ₹57.2 Cr / PBT ₹250.9 Cr), essentially in line with management's prior-concall guidance of ~22% for the FY27 core business — guidance met. Management gave no formal quarterly revenue/PAT guidance this print, only the FY30 'True North' target to triple EBITDA to ~₹3,000 Cr, contingent on TruBridge integration. Against the Street: Univest/Uniresearch's pre-result trailing-growth preview had pegged Q1 FY27 revenue at ₹820-943 Cr and PAT at ₹186-237 Cr; the actual ₹893.6 Cr revenue and ₹193.7 Cr PAT both landed inside that range, revenue toward the upper-middle and PAT toward the lower end — an inline print rather than a beat. Analyst target-price clustering of ₹1,880-1,900 versus a pre-result price near ₹1,848.9 (per the same preview) implied only modest upside, with the Street debate centred on TruBridge integration risk (net debt ~$2,500 Cr, ~15-16x EBITDA pre-synergy) against the deal's asset quality (~$347M revenue, ~20% EBITDA conversion). This quarter's corporate actions largely support that integration narrative: the $557M TruBridge acquisition closed July 9, 2026 (a non-adjusting subsequent event, though a pre-existing software-license sale to TruBridge was recognized as revenue this quarter), ARAI Solutions was consolidated from May 14, 2026 for ₹11 Cr cash, and IKS Inc. raised its stake in IKS WWMG MSO LLC to 51.88% on the last day of the quarter (no P&L impact yet, still equity-accounted). The Board separately approved the retirement of Non-Executive Chairman Berjis Desai post-AGM and designated Clarence Carleton King II as his successor, unrelated to the financial print. Q2 FY27 becomes the first quarter to consolidate TruBridge's revenue and cost base — a step-change in scale and leverage — so integration execution, not the still-strong organic India growth, will be the swing factor for margin trajectory and any FY27-28 guidance refinement.